Federal Register / Vol. 74, No. 100 / Wednesday, May 27, 2009 / Notices 25241 

Request for Comment 

Comments are invited on: 

a. Whether the information collection 

is necessary for the proper performance 

of the agencies’ functions, including 

whether the information has practical 

utility; 

b. The accuracy of the agencies’ 

estimate of the burden of the 

information collection, including the 

validity of the methodology and 

assumptions used; 

c. Ways to enhance the quality, 

utility, and clarity of the information to 

be collected; 

d. Ways to minimize the burden of the 

information collection on respondents, 

including through the use of automated 

collection techniques or other forms of 

information technology; and 

e. Estimates of capital or start up costs 

and costs of operation, maintenance, 

and purchase of services to provide 

information. 

Comments submitted in response to 

this notice will be shared among the 

agencies. All comments will become a 

matter of public record. Written 

comments should address the accuracy 

of the burden estimate and ways to 

minimize burden including the use of 

automated collection techniques or the 

use of other forms of information 

technology as well as other relevant 

aspects of the information collection 

request. 

Board of Governors of the Federal Reserve 

System, May 21, 2009. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E9–12249 Filed 5–26–09; 8:45 am] 

BILLING CODE 6210–01–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR Part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The applications listed below, as well 

as other related filings required by the 

Board, are available for immediate 

inspection at the Federal Reserve Bank 

indicated. The applications also will be 

available for inspection at the offices of 

the Board of Governors. Interested 

persons may express their views in 

writing on the standards enumerated in 

the BHC Act (12 U.S.C. 1842(c)). If the 

proposal also involves the acquisition of 

a nonbanking company, the review also 

includes whether the acquisition of the 

nonbanking company complies with the 

standards in section 4 of the BHC Act 

(12 U.S.C. 1843). Unless otherwise 

noted, nonbanking activities will be 

conducted throughout the United States. 

Additional information on all bank 

holding companies may be obtained 

from the National Information Center 

website at www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than June 22, 2009. 

Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. Hantz Holdings, Inc., Southfield, 

Michigan; to become a bank holding 

company by acquiring 100 percent of 

the voting shares of Davison State Bank, 

Davison, Michigan. 

In connection with this application, 

Applicant also has applied to acquire 

Tranex Financial, Inc., Southfield, 

Michigan, and thereby engage in making 

and servicing loans, pursuant to section 

225.28(b)(1) of Regulation Y. 

Board of Governors of the Federal Reserve 

System, May 21, 2009. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc.E9–12277 Filed 5–26–09; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Notice of Proposals to Engage in 

Permissible Nonbanking Activities or 

to Acquire Companies that are 

Engaged in Permissible Nonbanking 

Activities 

The companies listed in this notice 

have given notice under section 4 of the 

Bank Holding Company Act (12 U.S.C. 

1843) (BHC Act) and Regulation Y (12 

CFR Part 225) to engage de novo, or to 

acquire or control voting securities or 

assets of a company, including the 

companies listed below, that engages 

either directly or through a subsidiary or 

other company, in a nonbanking activity 

that is listed in § 225.28 of Regulation Y 

(12 CFR 225.28) or that the Board has 

determined by Order to be closely 

related to banking and permissible for 

bank holding companies. Unless 

otherwise noted, these activities will be 

conducted throughout the United States. 

Each notice is available for inspection 

at the Federal Reserve Bank indicated. 

The notice also will be available for 

inspection at the offices of the Board of 

Governors. Interested persons may 

express their views in writing on the 

question whether the proposal complies 

with the standards of section 4 of the 

BHC Act. Additional information on all 

bank holding companies may be 

obtained from the National Information 

Center website at www.ffiec.gov/nic/. 

Unless otherwise noted, comments 

regarding the applications must be 

received at the Reserve Bank indicated 

or the offices of the Board of Governors 

not later than June 22, 2009. 

A. Federal Reserve Bank of Atlanta 

(Steve Foley, Vice President) 1000 

Peachtree Street, N.E., Atlanta, Georgia 

30309: 

1. First America Holdings 

Corporation, Osprey, Florida; to acquire 

100 percent of the voting shares of 

MRCB Holdings, Inc., Palmetto, Florida, 

and thereby engage in operating a 

savings association, pursuant to section 

225.28(b)(4)(ii) of Regulation Y. 

Board of Governors of the Federal Reserve 

System, May 21, 2009. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E9–12276 Filed 5–26–09; 8:45 am] 

BILLING CODE 6210–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Toxicology Program (NTP); 

Office of Liaison, Policy and Review 

Meeting of the NTP Board of Scientific 

Counselors 

AGENCY: National Institute of 

Environmental Health Sciences 

(NIEHS), National Institutes of Health. 

ACTION: Meeting announcement and 

request for comments. 

SUMMARY: Pursuant to Public Law 92– 

463, notice is hereby given of a meeting 

of the NTP Board of Scientific 

Counselors (BSC). The BSC is a 

federally chartered, external advisory 

group composed of scientists from the 

public and private sectors that provides 

primary scientific oversight to the NTP 

Director and evaluates the scientific 

merit of the NTP’s intramural and 

collaborative programs. 

DATES: The BSC meeting will be held on 

July 23–24, 2009. The deadline for 

submission of written comments is July 

9, 2009, and for pre-registration to 

attend the meeting, including registering 


erowe on PROD1PC63 with NOTICES
25242 Federal Register / Vol. 74, No. 100 / Wednesday, May 27, 2009 / Notices 

to present oral comments, is July 16, 

2009. Persons needing interpreting 

services in order to attend should 

contact 301–402–8180 (voice) or 301– 

435–1908 (TTY). For other 

accommodations while on the NIEHS 

campus, contact 919–541–2475 or email niehsoeeo@niehs.nih.gov. Requests 

should be made at least 7 days in 

advance of the event. 

ADDRESSES: The BSC meeting will be 

held in the Rodbell Auditorium, Rall 

Building, at the NIEHS, 111 T.W. 

Alexander Drive, Research Triangle 

Park, NC 27709. Public comments on all 

agenda topics and any other 

correspondence should be submitted to 

Dr. Barbara Shane, Executive Secretary 

for the BSC, NTP Office of Liaison, 

Policy and Review, NIEHS, P.O. Box 

12233, MD K2–03, Research Triangle 

Park, NC 27709; telephone: 919–541– 

4253; fax: 919–541–0295; or e-mail: 

shane@niehs.nih.gov. Courier address: 

NIEHS, 530 Davis Drive, Room K 2138, 

Research Triangle Park, NC 27713. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Barbara Shane (telephone: 919–541– 

4253 or e-mail: shane@niehs.nih.gov). 

SUPPLEMENTARY INFORMATION: 

Preliminary Agenda Topics and 

Availability of Meeting Materials 

• Update of NTP Activities. 

• Report of the Technical Reports 

Review Subcommittee Meeting held 

February 25, 2009. 

• NTP Testing Program: Nominations 

and Proposed Research Projects on 

alkylanilines, p-chlorobenzotrifluoride, 

deoxynivalenol, Dong quai, indium tin 

oxide, and tris(4-chlorophenyl)methane 

and tris(4-chlorophenyl)methanol. 

• Contract Concept Review: 

Investigative ADME Studies of 

Toxicants in NTP Animal Model 

Systems. 

• Contract Concept Review: 

Toxicology and Carcinogenicity Studies. 

• Contract Concept Review: Report on 

Carcinogens Support Contract. 

• Interagency Agreements with Food 

and Drug Administration/National 

Center for Toxicological Research and 

Centers for Disease Control and 

Prevention/National Institute for 

Occupational Safety and Health. 

The preliminary agenda, roster of BSC 

members, draft NTP research concepts, 

public comments, and any additional 

information, when available, will be 

posted on the BSC meeting Web site 

(http://ntp.niehs.nih.gov/go/165) or may 

be requested in hardcopy from the 

Executive Secretary for the BSC (see 

ADDRESSES above). Any updates to the 

agenda will also be posted to this site. 

Following the meeting, summary 

minutes will be prepared and made 

available on the NTP meeting Web site. 

NTP Testing Program: Nominations and 

Proposed Research Projects 

The NTP actively seeks to identify 

and select for study chemicals and other 

substances for which sufficient 

information is not available to 

adequately evaluate potential human 

health hazards. The NTP accomplishes 

this goal through a formal, open 

nomination and selection process. 

Substances considered appropriate for 

study generally fall into two broad, yet 

overlapping categories: (1) Substances 

judged to have high concern as possible 

public health hazards based on the 

extent of human exposure and/or 

suspicion of toxicity and (2) substances 

for which toxicological data gaps exist 

and additional studies would aid in 

assessing potential human health risks, 

e.g., by facilitating cross-species 

extrapolation or evaluating doseresponse relationships. Nominations are 

subject to a multi-step, formal process of 

review before selections for testing are 

made and toxicological studies are 

designed and implemented. The 

nomination review and selection 

process is accomplished through the 

participation of representatives from the 

NIEHS, other federal agencies 

represented on the Interagency 

Committee for Chemical Evaluation and 

Coordination (ICCEC), the BSC, the NTP 

Executive Committee—the NTP federal 

interagency policy body, and the public. 

The nomination review and selection 

process is described in further detail on 

the NTP Web site (http:// 

ntp.niehs.nih.gov/, select ‘‘Nominations 

to the Testing Program’’). 

Table 1 lists new nominations to be 

reviewed at the BSC meeting. 

Background documents for each 

nomination are available on the NTP 

Web site http://ntp.niehs.nih.gov/go/ 

nom. The NTP invites interested parties 

to submit written comments, provide 

supplementary information, or present 

oral comments at the BSC meeting on 

the nominated substances and 

preliminary study recommendations 

(see ‘‘Request for Comments’’ below). 

The NTP welcomes toxicology study 

information from completed, ongoing, 

or anticipated studies, as well as 

information on current U.S. production 

levels, use or consumption patterns, 

human exposure, environmental 

occurrence, or public health concerns 

for any of the nominated substances. 

The NTP is interested in identifying 

appropriate animal and non-animal 

experimental models for mechanisticbased research, including genetically 

modified rodents and high-throughput 

in vitro test methods, and as such, 

solicits comments regarding the use of 

specific in vivo and in vitro 

experimental approaches to address 

questions relevant to the nominated 

substances and issues under 

consideration. Although the deadline 

for submission of written comments to 

be considered at the BSC meeting is July 

9, 2009 (see ‘‘Request for Comments’’ 

below), the NTP welcomes comments or 

additional information on these study 

nominations at any time. 

TABLE 1—TESTING RECOMMENDATIONS FOR SUBSTANCES NOMINATED TO THE NTP FOR TOXICOLOGICAL STUDIES

Substance 

[CAS No.] Nomination source Nomination rationale Preliminary study recommendations 

Alkylanilines ...................................

2–Ethylaniline [578–54–1] 

3–Ethylaniline [587–02–0] 

3,5–Dimethylaniline [108–69–0] 

National Institute of Environmental 

Health Sciences1.

Potential for human exposure 

from a variety of industrial and 

ambient sources; suspicion of 

toxicity based on chemical 

structure; insufficient data to 

characterize toxicity of this aniline subclass.

Initial toxicological characterization. 

p-Chlorobenzotrifluoride [98–56–6] Kowa American Corp. .................. High production volume; increasing industrial and potential consumer use; lack of workplace 

exposure standards; lack of 

chronic toxicity data.

Comprehensive toxicological characterization including developmental and reproductive toxicity 

and chronic toxicity/carcinogenicity studies. 


erowe on PROD1PC63 with NOTICES
Federal Register / Vol. 74, No. 100 / Wednesday, May 27, 2009 / Notices 25243 

TABLE 1—TESTING RECOMMENDATIONS FOR SUBSTANCES NOMINATED TO THE NTP FOR TOXICOLOGICAL STUDIES— 

Continued 

Substance 

[CAS No.] Nomination source Nomination rationale Preliminary study recommendations 

Deoxynivalenol [51481–10–8] ....... NIEHS ........................................... Widespread environmental occurrence and potential for human 

exposure through consumption 

of contaminated foods; demonstrated toxicological activity; 

lack of definitive carcinogenicity 

and reproductive toxicity studies.

Comprehensive toxicological characterization including reproductive toxicity and chronic toxicity/ 

carcinogenicity studies. 

Dong quai (Angelica sinensis root 

[308068–61–3] and extract 

[299184–76–2]).

Private Individual .......................... Widespread use as a dietary supplement; suspicion of toxicity 

based on estrogenic activity 

and chemical structure; lack of 

adequate toxicity data.

Comprehensive toxicological characterization including phototoxicity studies. 

Indium tin oxide [50926–11–9] ...... NIEHS ........................................... Increasing production and use; 

documented pulmonary effects 

in exposed workers; suspicion 

of toxicity based on chemical 

structure; lack of adequate toxicity data.

Comprehensive toxicological characterization. 

Tris(4-chlorophenyl)methane 

[27575–78–6] and Tris(4- 

chlorophenyl)methanol [3010– 

80–8].

NIEHS ........................................... Widespread occurrence and persistence in the environment; 

suspicion of toxicity based on 

anti-androgenic activity; lack of 

adequate toxicity data.

Initial toxicological characterization. 

1 National Institute of Environmental Health Sciences (NIEHS) 

2The terms ‘‘initial’’ and ‘‘comprehensive toxicological characterization’’ in this table refer to the approximate scope of a research program to 

address toxicological data needs. The types of toxicological studies that would be considered by NTP staff during the conceptualization and design of a research program are: 

• Initial toxicological characterization: biomolecular screening, in vitro mechanistic, in vitro and in vivo genotoxicity, absorption, disposition, metabolism, and elimination, and short-term repeat dose (2–4 weeks) in vivo studies. 

• Comprehensive toxicological characterization: all of the aforementioned plus subchronic toxicity (13–26 weeks), chronic toxicity (1–2 years), 

carcinogenicity in conventional or genetically modified rodent models, organ systems toxicity (immunotoxicity, reproductive and developmental 

toxicity, neurotoxicity), in vivo mechanistic, toxicokinetics, and other special studies as appropriate (e.g., chemistry, toxicogenomics, 

phototoxicity). 

To facilitate review of proposed 

research projects by the BSC and the 

public, NTP staff developed a draft 

research concept document for each 

nomination recommended for study. A 

research concept is a brief document 

outlining the nomination or study 

rationale, and the significance, study 

approach, and expected outcome of a 

proposed research program tailored for 

each nomination. The purpose of these 

research concepts is to outline the 

general elements of a program of study 

that would address the specific issues 

that prompted the nomination, but also 

encompass studies that may address 

larger public health issues or topics in 

toxicology that could be addressed 

appropriately through studies on the 

nominated substance(s). Draft research 

concepts for the new nominations listed 

in Table 1 will be available on the BSC 

meeting page (http://ntp.niehs.nih.gov/ 

go/165) by June 8, 2009. 

Attendance and Registration 

The meeting is scheduled for July 23– 

24, 2009, beginning at 8:30 a.m. on each 

day and continuing to 5 p.m. on July 23 

and on July 24 until adjournment. The 

meeting is open to the public with 

attendance limited only by the space 

available. Individuals who plan to 

attend are encouraged to register online 

at the BSC meeting Web site (http:// 

ntp.niehs.nih.gov/go/165) by July 16, 

2009, to facilitate planning for the 

meeting. The NTP is making plans to 

videocast the meeting through the 

Internet at http://www.niehs.nih.gov/ 

news/video/live. 

Request for Comments 

Written comments submitted in 

response to this notice should be 

received by July 9, 2009. Comments will 

be posted on the BSC meeting Web site 

and persons submitting them will be 

identified by their name and affiliation 

and/or sponsoring organization, if 

applicable. Persons submitting written 

comments should include their name, 

affiliation (if applicable), phone, e-mail, 

and sponsoring organization (if any) 

with the document. 

Time will be allotted during the 

meeting for the public to present oral 

comments to the BSC on the agenda 

topics. Each organization is allowed one 

time slot per agenda topic. At least 7 

minutes will be allotted to each speaker, 

and if time permits, may be extended to 

10 minutes at the discretion of the BSC 

chair. Persons wishing to present oral 

comments are encouraged to pre-register 

on the NTP meeting Web site by July 16. 

Registration for oral comments will also 

be available on-site, although time 

allowed for presentation by on-site 

registrants may be less than that for preregistered speakers and will be 

determined by the number of persons 

who register at the meeting. 

Persons registering to make oral 

comments are asked, if possible, to send 

a copy of their statement to the 

Executive Secretary for the BSC (see 

ADDRESSES above) by July 16, 2009. 

Written statements can supplement and 

may expand the oral presentation. If 

registering on-site and reading from 

written text, please bring 40 copies of 

the statement for distribution to the BSC 

and NIEHS/NTP staff and to supplement 

the record. 

Background Information on the NTP 

Board of Scientific Counselors 

The BSC is a technical advisory body 

comprised of scientists from the public 

and private sectors that provides 

primary scientific oversight to the 

overall program and its centers. 


erowe on PROD1PC63 with NOTICES
25244 Federal Register / Vol. 74, No. 100 / Wednesday, May 27, 2009 / Notices 

Specifically, the BSC advises the NTP 

on matters of scientific program content, 

both present and future, and conducts 

periodic review of the program for the 

purpose of determining and advising on 

the scientific merit of its activities and 

their overall scientific quality. Its 

members are selected from recognized 

authorities knowledgeable in fields such 

as toxicology, pharmacology, pathology, 

biochemistry, epidemiology, risk 

assessment, carcinogenesis, 

mutagenesis, molecular biology, 

behavioral toxicology, neurotoxicology, 

immunotoxicology, reproductive 

toxicology or teratology, and 

biostatistics. Members serve overlapping 

terms of up to four years. BSC meetings 

are held annually or biannually. 

Dated: May 15, 2009. 

John R. Bucher, 

Associate Director, National Toxicology 

Program. 

[FR Doc. E9–12204 Filed 5–26–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; Comment 

Request; REDS–II Donor Iron Status 

Evaluation (RISE) Study 

Summary: Under the provisions of 

Section 3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Heart, Lung, and Blood Institute 

(NHLBI), the National Institutes of 

Health (NIH) has submitted to the Office 

of Management and Budget (OMB) a 

request to review and approve the 

information collection listed below. 

This proposed information collection 

was previously published in the Federal 

Register on March 9, 2009, pages 

10057–10058 and allowed 60-days for 

public comment. No comments were 

received in response to this notice. The 

purpose of this notice is to allow an 

additional 30 days for public comment. 

The National Institutes of Health may 

not conduct or sponsor, and the 

respondent is not required to respond 

to, an information collection that has 

been extended, revised, or implemented 

on or after October 1, 1995, unless it 

displays a current valid OMB control 

number. 

Proposed Collection 

Title: REDS–II Donor Iron Status 

Evaluation (RISE) Study. Type of 

Information Collection Request: 

Revision of a currently approved 

collection. OMB control #0925–0581. 

Expiration Date: 05/31/2009. Need and 

Use of Information Collection: Although 

the overall health significance of iron 

depletion in blood donors is uncertain, 

iron depletion leading to iron deficient 

erythropoiesis and lowered hemoglobin 

levels results in donor deferral and, 

occasionally, in mild iron deficiency 

anemia. Hemoglobin deferrals represent 

more than half of all donor deferral, 

deferring 16% of women. The RISE 

Study is a longitudinal study of iron 

status in two cohorts of blood donors: a 

first time/reactivated donor cohort in 

which baseline iron and hemoglobin 

status can be assessed without the 

influence of previous donations, and a 

frequent donor cohort, where the 

cumulative effect of additional frequent 

blood donations can be assessed. Each 

cohort’s donors will donate blood and 

provide evaluation samples during the 

study period. 

The primary goal of the study is to 

evaluate the effects of blood donation 

intensity on iron and hemoglobin status 

and assess how these are modified as a 

function of baseline iron/hemoglobin 

measures, demographic factors, and 

reproductive and behavioral factors. 

Hemoglobin levels, a panel of iron 

protein, red cell and reticulocyte indices 

will be measured at baseline and at a 

final follow-up visit 15–24 months after 

the baseline visit. A DNA sample will be 

obtained once at the baseline visit to 

assess three key iron protein 

polymorphisms. Donors will also 

complete a self-administered survey 

assessing past blood donation, smoking 

history, use of vitamin/mineral 

supplements, iron supplements, aspirin, 

frequency of heme rich food intake, and, 

for females, menstrual status and 

pregnancy history at these two time 

points. This study aims to identify the 

optimal laboratory measures that would 

predict the development of iron 

depletion, hemoglobin deferral, and/or 

iron deficient hemoglobin deferral in 

active whole blood and double red cell 

donors at subsequent blood donations. 

The data collected will help evaluate 

hemoglobin distributions in the blood 

donor population (eligible and deferred 

donors) and compare them with 

NHANES data. Other secondary 

objectives include elucidating key 

genetic influences on hemoglobin levels 

and iron status in a donor population as 

a function of donation history; and 

establishing a serum and DNA archive 

to evaluate the potential utility of future 

iron studies and genetic 

polymorphisms. 

This study will develop better 

predictive models for iron depletion and 

hemoglobin deferral (with or without 

iron deficiency) in blood donors; allow 

for the development of improved donor 

screening strategies and open the 

possibility for customized donation 

frequency guidelines for individuals or 

classes of donors; provide important 

baseline information for the design of 

targeted iron supplementation strategies 

in blood donors, and improved 

counseling messages to blood donors 

regarding diet or supplements; and by 

elucidating the effect of genetic iron 

protein polymorphisms on the 

development of iron depletion, enhance 

the understanding of the role of these 

proteins in states of iron stress, using 

frequent blood donation as a model. 

This request for modification is to add 

eleven questions to the RISE study final 

visit questionnaire that will include 

questions about Restless Leg Syndrome 

(RLS) and pica, two disorders associated 

with iron deficiency. RLS is a 

neurologic movement disorder in which 

patients complain of crawling, aching or 

indescribable feelings in their legs or 

just have the need to move. Pica is an 

eating disorder defined as compulsive 

ingestion of non-food substances. Blood 

donation results in the removal of 200– 

250 mg of iron from the donor. It is well 

established that repeated blood 

donation can produce iron deficiency, 

yet the prevalence of RLS and pica 

among blood donors is unknown. The 

REDS–II RISE study subjects are an 

ideal study population for the 

investigation of RLS and pica in blood 

donors. About 2,400 subjects with 

variable donation intensity (e.g. 

frequency with which a person donates 

blood) are currently enrolled in the RISE 

Study. The iron status of all of these 

subjects is well characterized, including 

measurement of plasma ferritin and 

soluble transferrin receptor along with 

hemoglobin/hematocrit. These 

laboratory values allow each subject to 

be defined as 1) iron replete, 2) iron 

deficient without anemia or 3) iron 

deficiency anemia. The responses to 

these questions will be correlated with 

the laboratory test values to determine 

the relationship between blood donation 

and the development of RLS and pica 

and will establish its prevalence in 

these populations. 

Frequency of Response: Twice. 

Affected Public: Individuals. Type of 

Respondents: Adult blood donors. The 

annual reporting burden is as follows: 

Estimated Number of Respondents: 

Baseline visit: 2,340, Follow up visit: 

1,530; Estimated Number of Responses 

per Respondent: 1; Average Burden of 

Hours per Response: Baseline Visit: 

0.37, Follow up Visit: 0.25; and 

Estimated Total Annual Burden Hours 

Requested: Baseline visit: 866, Follow 

up Visit: 383. The annualized cost to 

respondents is estimated at: Baseline 


erowe on PROD1PC63 with NOTICES